Business
New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway
5W AI Communications, the AI Communications Firm and one of the largest independent public relations and digital marketing agencies in the United States, today released the Pharma / Rx AI Visibility Index 2026, with a focused cut on the gap between pharmaceutical direct-to-consumer ad spend and AI citation share. The Index is part of the 5W AI Visibility Index series, which tracks how leading brands are cited across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews.
About this update from Eli Lilly And Company
Drugmakers run the largest direct-to-consumer advertising category in the United States. New 5W research finds AI citation share does not follow the ad budget — it follows the drugs patients self-research. Eli Lilly and Novo Nordisk lead the answer. Merck makes the world's best-selling drug and ranks fifth. BOCA RATON, Fla., June 19, 2026 /PRNewswire/ -- 5W AI Communications, the AI Communications Firm and one of the largest independent public relations and digital marketing agencies in the United States, today released the Pharma / Rx AI Visibility Index 2026, with a focused cut on the gap between pharmaceutical direct-to-consumer ad spend and AI citation share. The Index is part of the 5W AI Visibility Index series, which tracks how leading brands are cited across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews. The Index ranks the top 25 pharmaceutical companies by AI citation share across more than 60 patient and consumer prompts run in Q2 2026 — five times per engine, in clean sessions. The Pharma DTC cut isolates one structural finding: the U.S. pharmaceutical industry spent an estimated $8 billion on direct-to-consumer advertising in 2024 — the largest category-level DTC ad commitment in the country — yet ad spend does not predict where the AI engines land. The headline numbers 12.5% — Estimated AI citation share held by Eli Lilly, the most-cited drugmaker.11.5% — Novo Nordisk, citation co-leader on the back of Ozempic and Wegovy.~$70 billion — Combined 2025 sales of Ozempic, Wegovy, Mounjaro, and Zepbound (GLP-1 receptor agonists).$5.6 trillion — Estimated size of the global pharmaceutical market.$1 trillion — Market cap milestone Eli Lilly briefly crossed — the first healthcare company to do so.5th — Where Merck lands in citation rank, despite producing Keytruda, the best-selling prescription drug in the world. The top fifteen drugmakers by AI citation share — Q2 2026 01. Eli Lilly — Metabolic & GLP-1 — 12.5%02. Novo Nordisk — Metabolic & GLP-1 — 11.5%03. Pfizer — Diversified / vaccines — 8.5%04. Johnson & Johnson — Diversified — 7.0%05. Merck — Oncology — 6.0%06. AbbVie — Immunology & inflammation — 5.0%07. AstraZeneca — Oncology & specialty — 4.0%08. Moderna — Vaccines & mRNA — 3.5%09. Amgen — Biologics & specialty — 3.0%10. Novartis — Specialty & gene therapy — 2.6%11. Bristol Myers Squibb ...
View stock analysis, news, and events for Eli Lilly And Company